Do you want to read an article? Please log in or register.
Tapering conventional synthetic DMARDs in patients with early arthritis in sustained remission: 2-year follow-up of the tREACH trial
Rheumatoid Arthritis
Related content
Psoriatic Arthritis
Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study
Arthritis Res Ther.
Coates LC, Gladman DD, Nash P, FitzGerald O, Kavanaugh A, Kvien TK, Gossec L, Strand V, Rasouliyan L, Pricop L, Ding K, Jugl SM, Gaillez C; FUTURE 2 study group
doi: 10.1186/s13075-018-1773-y.
Rheumatoid Arthritis
Tapering towards DMARD-free remission in established rheumatoid arthritis: 2-year results of the TARA trial
Ann Rheum Dis.
van Mulligen E, Weel AE, Hazes JM, van der Helm-van Mil A, de Jong PHP
doi: 10.1136/annrheumdis-2020-217485.
Rheumatoid Arthritis
Clinical benefit of 1-year certolizumab pegol (CZP) add-on therapy to methotrexate treatment in patients with early rheumatoid arthritis was observed following CZP discontinuation: 2-year results of the C-OPERA study, a phase III randomised trial
Ann Rheum Dis.
Atsumi T, Tanaka Y, Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, Eguchi K, Watanabe A, Origasa H, Yasuda S, Yamanishi Y, Kita Y, Matsubara T, Iwamoto M, Shoji T, Togo O, Okada T, van der Heijde D, Miyasaka N, Koike T
doi: 10.1136/annrheumdis-
Rheumatoid Arthritis
Gradual tapering TNF inhibitors versus conventional synthetic DMARDs after achieving controlled disease in patients with rheumatoid arthritis: first-year results of the randomised controlled TARA study
Ann Rheum Dis.
van Mulligen E, de Jong PHP,
Kuijper TM, van der Ven M, Appels C, Bijkerk C, Harbers JB, de Man Y, Molenaar THE, Tchetverikov I, Goekoop-Ruiterman YPM, van Zeben J, Hazes JMW, Weel AEAM, Luime JJ
doi: 10.1136/annrheumdis-2018-214970.
Rheumatoid Arthritis
Effect of Half-Dose vs Stable-Dose Conventional Synthetic Disease-Modifying Antirheumatic Drugs on Disease Flares in Patients With Rheumatoid Arthritis in Remission: The ARCTIC REWIND Randomized Clinical Trial
JAMA
Lillegraven S, Paulshus Sundlisæter N, Aga AB, Sexton J, Olsen IC, Fremstad H, Spada C, Madland TM, Høili CA, Bakland G, Lexberg Å, Hansen IJW, Hansen IM, Haukeland H, Ljoså MA, Moholt E, Uhlig T, Solomon DH, van der Heijde D, Kvien TK, Haavardsholm EA
doi: 10.1001/jama.2021.4542
Rheumatoid Arthritis
Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study.
Ann Rheum Dis.
Emery P, Bingham CO, Burmester GR, Bykerk VP, Furst DE, Mariette X, van der Heijde D, van Vollenhoven R, Arendt C, Mountian I, Purcaru O, Tatla D, VanLunen B, Weinblatt ME
doi: 10.1136/
COMMENTED
Rheumatoid Arthritis
Predictors of good response to conventional synthetic DMARDs in early seronegative rheumatoid arthritis: data from the ESPOIR cohort
★ 2
Recommended and commented by
Dr Heino Prillwitz, Faculty Member
Arthritis Res Ther.
Lukas C, Mary J, Debandt M, Daïen C, Morel J, Cantagrel A, Fautrel B, Combe B
doi: 10.1186/s13075-019-2020-x.
Rheumatoid Arthritis
Does immunological remission, defined as disappearance of autoantibodies, occur with current treatment strategies? A long-term follow-up study in rheumatoid arthritis patients who achieved sustained DMARD-free status
Ann Rheum Dis.
Boeters DM, Burgers LE, Toes RE, van der Helm-van Mil A
doi: 10.1136/annrheumdis-2018-214868.
COMMENTED
Rheumatoid Arthritis
Normal mortality of the COBRA early rheumatoid arthritis trial cohort after 23 years of follow-up
Ann Rheum Dis.
Poppelaars PB, van Tuyl LHD, Boers M
doi: 10.1136/annrheumdis-2018-214618.